Alvotech (ALVO) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vericel (VCEL) has outperformed Alvotech (ALVO) over the past year, gaining 17.3% versus a loss of 34.7%. Vericel is the larger company by market cap ($2.05 billion vs $2.02 billion), about 1.0 times the size. On valuation, Alvotech trades at a lower forward P/E (24.8x vs 47.3x for Vericel).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | VCEL |
|---|---|---|
| Share price | $5.67 | $40.05 |
| Market cap | $2.02B | $2.05B |
| 1-day change | -3.08% | -1.69% |
| YTD return | +10.53% | +11.22% |
| 1-year return | -34.68% | +17.35% |
| 5-year return | — | -19.79% |
| P/E ratio (TTM) | — | 85.21 |
| Forward P/E | 24.83 | 47.34 |
| EPS (TTM) | $-0.62 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.05 | $49.32 |
| 52-week low | $2.94 | $28.95 |
| Distance from 52-week high | -37.31% | -18.80% |
| Analyst consensus | none | none |
| Avg. price target upside | +19.93% | +51.24% |
| Average volume | 1.05M | 502.23K |
| Shares outstanding | 356.82M | 51.21M |
| Employees | 1,279 | 398 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCEL has outperformed ALVO by 52.0 percentage points over the past year.
- The two companies sit in different sectors: Alvotech in Health Care and Vericel in Healthcare.
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Healthcare · Biotechnology · 398 employees
ALVO vs VCEL FAQ
Which is bigger, Alvotech or Vericel?
Vericel (VCEL) is larger, with a market capitalization of $2.05B compared with $2.02B for Alvotech (ALVO).
Which stock has performed better over the past year, ALVO or VCEL?
VCEL returned +17.35% over the past 12 months, compared with -34.68% for ALVO (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Vericel in the same industry?
No. Alvotech is in the Health Care sector, while Vericel is in Healthcare.